Vaccine stocks tumbled Friday after the Centers for Disease Control and Prevention authorized a mix-and-match strategy for Covid booster shots. Move came with the authorization of booster shots for all recipients of the Johnson & Johnson (JNJ) vaccine and for at-risk adults who received the Moderna (MRNA) vaccination series. Moderna stock tumbled 3.8% to 326.54 after receiving a sell rating from Deutsche Bank. Fellow vaccine stock BioNTech tumbled 2.8 percent to 278.34. "IBD NewslettersGet exclusive IBD analysis and actionable news daily. Committee members backed the mix-and-match strategy to help prevent side effects in some populations. Pfizer and J&J stocks both tiptoed a fraction into the green. All adults who received the J&s;J shot are eligible for a booster two months after their first shot. Vaccine stocks have trended mostly sideways this month on worries a Covid pill from Merck will undercut immunizations. People age 65 and older, and adults who live in long-term care settings, have underlying medical conditions or work/live in high-risk settings can get a booster six months after their Moderna shots. Talbot says she hopes the clinical considerations, written recommendations accompanying each vaccine, would steer young women away from the J&J shot. Outside products from vaccine makers, companies like Regeneron Pharmaceuticals (REGN), Eli Lilly (LLY) and Vir Biotechnology (VIR) also are working on antiviral pills.
Posted by
Tap to copy the Short Url to this post: 
All Business News on a Single Page. Join for Free →